A phase II study to determine the safety and anti-leukemic effects of STI571 [imatinib] in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia

Trial Profile

A phase II study to determine the safety and anti-leukemic effects of STI571 [imatinib] in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2006

At a glance

  • Drugs Imatinib (Primary)
  • Indications Leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top